Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, García-Macías MDC, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J, de Álava E. Ordóñez JL, et al. Oncotarget. 2017 Jun 27;8(26):43592. doi: 10.18632/oncotarget.18610. Oncotarget. 2017. PMID: 28672777 Free PMC article. No abstract available.
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, del Carmen García-Macías M, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J, de Álava E. Ordóñez JL, et al. Oncotarget. 2015 Aug 7;6(22):18875-90. doi: 10.18632/oncotarget.4303. Oncotarget. 2015. PMID: 26056084 Free PMC article.
Glucosylated nanomicelles target glucose-avid pediatric patient-derived sarcomas.
Bukchin A, Pascual-Pasto G, Cuadrado-Vilanova M, Castillo-Ecija H, Monterrubio C, Olaciregui NG, Vila-Ubach M, Ordeix L, Mora J, Carcaboso AM, Sosnik A. Bukchin A, et al. J Control Release. 2018 Apr 28;276:59-71. doi: 10.1016/j.jconrel.2018.02.034. Epub 2018 Feb 28. J Control Release. 2018. PMID: 29501533
The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma.
García-Domínguez DJ, Hontecillas-Prieto L, Rodríguez-Núñez P, Pascual-Pasto G, Vila-Ubach M, García-Mejías R, Robles MJ, Tirado OM, Mora J, Carcaboso AM, de Álava E. García-Domínguez DJ, et al. Oncotarget. 2018 Jul 31;9(59):31397-31410. doi: 10.18632/oncotarget.25829. eCollection 2018 Jul 31. Oncotarget. 2018. PMID: 30140378 Free PMC article.
Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution.
Castillo-Ecija H, Monterrubio C, Pascual-Pasto G, Gomez-Gonzalez S, Garcia-Dominguez DJ, Hontecillas-Prieto L, Resa-Pares C, Burgueño V, Paco S, Olaciregui NG, Vila-Ubach M, Restrepo-Perdomo C, Cuadrado-Vilanova M, Balaguer-Lluna L, Perez-Jaume S, Castañeda A, Santa-Maria V, Roldan M, Suñol M, de Alava E, Mora J, Lavarino C, Carcaboso AM. Castillo-Ecija H, et al. J Control Release. 2020 Aug 10;324:440-449. doi: 10.1016/j.jconrel.2020.05.032. Epub 2020 Jun 1. J Control Release. 2020. PMID: 32497782
Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma.
García-Domínguez DJ, Hajji N, Sánchez-Molina S, Figuerola-Bou E, de Pablos RM, Espinosa-Oliva AM, Andrés-León E, Terrón-Camero LC, Flores-Campos R, Pascual-Pasto G, Robles MJ, Machado I, Llombart-Bosch A, Magagnoli G, Scotlandi K, Carcaboso ÁM, Mora J, de Álava E, Hontecillas-Prieto L. García-Domínguez DJ, et al. Oncogene. 2021 Sep;40(39):5843-5853. doi: 10.1038/s41388-021-01974-4. Epub 2021 Aug 3. Oncogene. 2021. PMID: 34345016 Free PMC article.
SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas.
Pascual-Pasto G, Castillo-Ecija H, Unceta N, Aschero R, Resa-Pares C, Gómez-Caballero A, Vila-Ubach M, Muñoz-Aznar O, Suñol M, Burgueño V, Gomez-Gonzalez S, Sosnik A, Ibarra M, Schaiquevich P, de Álava E, Tirado OM, Mora J, Carcaboso AM. Pascual-Pasto G, et al. J Control Release. 2022 Feb;342:81-92. doi: 10.1016/j.jconrel.2021.12.035. Epub 2021 Dec 30. J Control Release. 2022. PMID: 34974029
Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma.
Pascual-Pasto G, Resa-Pares C, Castillo-Ecija H, Aschero R, Baulenas-Farres M, Vila-Ubach M, Burgueño V, Balaguer-Lluna L, Cuadrado-Vilanova M, Olaciregui NG, Martinez-Velasco N, Perez-Jaume S, de Alava E, Tirado OM, Lavarino C, Mora J, Carcaboso AM. Pascual-Pasto G, et al. Biochem Pharmacol. 2023 Feb;208:115408. doi: 10.1016/j.bcp.2022.115408. Epub 2023 Jan 2. Biochem Pharmacol. 2023. PMID: 36603685
Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination.
Pascual-Pasto G, Olaciregui NG, Vila-Ubach M, Paco S, Monterrubio C, Rodriguez E, Winter U, Batalla-Vilacis M, Catala J, Salvador H, Parareda A, Schaiquevich P, Suñol M, Mora J, Lavarino C, de Torres C, Chantada GL, Carcaboso AM. Pascual-Pasto G, et al. Cancer Lett. 2016 Sep 28;380(1):10-9. doi: 10.1016/j.canlet.2016.06.012. Epub 2016 Jun 16. Cancer Lett. 2016. PMID: 27319373
27 results